首页> 外文期刊>Oncology: International Journal of Cancer Research and Treatment >Prognostic Indicators for Tumor Recurrence after Liver Transplantation in Hepatocellular Carcinoma and Related Molecular Targeted Therapy
【24h】

Prognostic Indicators for Tumor Recurrence after Liver Transplantation in Hepatocellular Carcinoma and Related Molecular Targeted Therapy

机译:肝细胞肝癌肝移植术后肿瘤复发的预后指标及相关分子靶向治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Liver transplantation (LT) is a viable therapeutic option for hepatocellular carcinoma (HCC). Many criteria, such as the Milan criteria and the University of California at San Francisco (UCSF) criteria, have been established to select a subset of HCC patients who stand to benefit from LT. However, they are still insufficient for predicting HCC patients at high risk for recurrence and selecting those at low risk. Many molecules which are probable candidates for recognizing HCC patients at high or low riskfor recurrence give a wider perspective to consider for LT indication. Besides working as bio-markers, most of them are also functionally involved in some important pathways which contribute to HCC metastasis. The complex network constituted by them shows a multichannel, multistep HCC metastatic process which indicates difficulty in tumor therapy. Given the efficacy of some molecular targeted drugs in the treatment of HCC or prevention of tumor recurrence after LT, the emerging molecular targeted therapy is also discussed in this review.
机译:肝移植(LT)是肝细胞癌(HCC)的可行治疗选择。已经建立了许多标准,例如米兰标准和加利福尼亚大学旧金山分校(UCSF)标准,以选择可以从LT中受益的HCC患者子集。但是,它们仍然不足以预测高复发风险的HCC患者并选择低风险的HCC患者。许多可能识别高复发风险或低复发风险的HCC患者的分子为LT适应症提供了更广阔的视野。除了充当生物标志物外,它们中的大多数还在功能上参与了一些有助于肝癌转移的重要途径。由它们构成的复杂网络显示出多通道,多步骤的HCC转移过程,这表明在肿瘤治疗中存在困难。考虑到某些分子靶向药物在治疗肝癌或预防LT后肿瘤复发方面的功效,本文还将讨论新兴的分子靶向疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号